Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The Q1 2025 also witnessed a successful launch of Allegra D
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Subscribe To Our Newsletter & Stay Updated